<DOC>
	<DOC>NCT02879981</DOC>
	<brief_summary>This pilot, multicentric and observational study will assess the of safety of sulfamethoxazole + trimethoprim + guaifenesin (Balsamic Bactrim) in pediatric participants with acute bronchitis. Administration of treatment will be according to physician's recommendation under local labeling.</brief_summary>
	<brief_title>A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
	<criteria>Participants starting treatment with Bactrim Balsamic suspension Participants with a clinical diagnosis of acute bronchitis according to the pulmonologist clinical criteria Participants who have started treatment with another antibiotic at the time of the visit Participants with no respiratory infections Participants with mental disorders Participants with severe hepatic parenchymal damage Participants with severe renal failure making it difficult to monitor drug plasma concentration Participants with hypersensitivity to any of Balsamic Bactrim active ingredients or excipients</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>